Dendritic cell-based vaccination in cancer: Therapeutic implications emerging from murine models
Dendritic cells (DCs) play a pivotal role in the orchestration of immune responses, and are thus key targets in cancer vaccine design. Since the 2010 FDA approval of the first cancer DC-based vaccine (Sipuleucel-T), there has been a surge of interest in exploiting these cells as a therapeutic option...
Guardado en:
| Autor principal: | |
|---|---|
| Publicado: |
2015
|
| Materias: | |
| Acceso en línea: | https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_16643224_v6_nMAY_p_MacKeon http://hdl.handle.net/20.500.12110/paper_16643224_v6_nMAY_p_MacKeon |
| Aporte de: |
| id |
paper:paper_16643224_v6_nMAY_p_MacKeon |
|---|---|
| record_format |
dspace |
| spelling |
paper:paper_16643224_v6_nMAY_p_MacKeon2023-06-08T16:26:04Z Dendritic cell-based vaccination in cancer: Therapeutic implications emerging from murine models Gazzaniga, Silvina N. Adjuvants Cancer immunotherapy Dendritic cell maturation Dendritic cell subsets Dendritic cell-based vaccines Dendritic cells CD103 antigen CD11b antigen dendritic cell vaccine imiquimod indoleamine 2, 3 dioxygenase inducible T cell costimulator interleukin 2 receptor ovalbumin pattern recognition receptor toll like receptor 7 toll like receptor adaptor molecule 1 tumor necrosis factor alpha unclassified drug antigen presenting cell bone marrow derived dendritic cell cancer model cancer therapy CD8+ T lymphocyte cytotoxic T lymphocyte dendritic cell human immune response Langerhans cell major histocompatibility complex monocyte mouse murine model neoplasm nonhuman phase 1 clinical trial (topic) plasmacytoid dendritic cell Review tumor microenvironment vaccination Dendritic cells (DCs) play a pivotal role in the orchestration of immune responses, and are thus key targets in cancer vaccine design. Since the 2010 FDA approval of the first cancer DC-based vaccine (Sipuleucel-T), there has been a surge of interest in exploiting these cells as a therapeutic option for the treatment of tumors of diverse origin. In spite of the encouraging results obtained in the clinic, many elements of DC-based vaccination strategies need to be optimized. In this context, the use of experimental cancer models can help direct efforts toward an effective vaccine design. This paper reviews recent findings in murine models regarding the antitumoral mechanisms of DC-based vaccination, covering issues related to antigen sources, the use of adjuvants and maturing agents, and the role of DC subsets and their interaction in the initiation of antitumoral immune responses. The summary of such diverse aspects will highlight advantages and drawbacks in the use of murine models, and contribute to the design of successful DC-based translational approaches for cancer treatment. © 2015 Mac Keon, Ruiz, Gazzaniga and Wainstok. Fil:Gazzaniga, S. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. 2015 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_16643224_v6_nMAY_p_MacKeon http://hdl.handle.net/20.500.12110/paper_16643224_v6_nMAY_p_MacKeon |
| institution |
Universidad de Buenos Aires |
| institution_str |
I-28 |
| repository_str |
R-134 |
| collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
| topic |
Adjuvants Cancer immunotherapy Dendritic cell maturation Dendritic cell subsets Dendritic cell-based vaccines Dendritic cells CD103 antigen CD11b antigen dendritic cell vaccine imiquimod indoleamine 2, 3 dioxygenase inducible T cell costimulator interleukin 2 receptor ovalbumin pattern recognition receptor toll like receptor 7 toll like receptor adaptor molecule 1 tumor necrosis factor alpha unclassified drug antigen presenting cell bone marrow derived dendritic cell cancer model cancer therapy CD8+ T lymphocyte cytotoxic T lymphocyte dendritic cell human immune response Langerhans cell major histocompatibility complex monocyte mouse murine model neoplasm nonhuman phase 1 clinical trial (topic) plasmacytoid dendritic cell Review tumor microenvironment vaccination |
| spellingShingle |
Adjuvants Cancer immunotherapy Dendritic cell maturation Dendritic cell subsets Dendritic cell-based vaccines Dendritic cells CD103 antigen CD11b antigen dendritic cell vaccine imiquimod indoleamine 2, 3 dioxygenase inducible T cell costimulator interleukin 2 receptor ovalbumin pattern recognition receptor toll like receptor 7 toll like receptor adaptor molecule 1 tumor necrosis factor alpha unclassified drug antigen presenting cell bone marrow derived dendritic cell cancer model cancer therapy CD8+ T lymphocyte cytotoxic T lymphocyte dendritic cell human immune response Langerhans cell major histocompatibility complex monocyte mouse murine model neoplasm nonhuman phase 1 clinical trial (topic) plasmacytoid dendritic cell Review tumor microenvironment vaccination Gazzaniga, Silvina N. Dendritic cell-based vaccination in cancer: Therapeutic implications emerging from murine models |
| topic_facet |
Adjuvants Cancer immunotherapy Dendritic cell maturation Dendritic cell subsets Dendritic cell-based vaccines Dendritic cells CD103 antigen CD11b antigen dendritic cell vaccine imiquimod indoleamine 2, 3 dioxygenase inducible T cell costimulator interleukin 2 receptor ovalbumin pattern recognition receptor toll like receptor 7 toll like receptor adaptor molecule 1 tumor necrosis factor alpha unclassified drug antigen presenting cell bone marrow derived dendritic cell cancer model cancer therapy CD8+ T lymphocyte cytotoxic T lymphocyte dendritic cell human immune response Langerhans cell major histocompatibility complex monocyte mouse murine model neoplasm nonhuman phase 1 clinical trial (topic) plasmacytoid dendritic cell Review tumor microenvironment vaccination |
| description |
Dendritic cells (DCs) play a pivotal role in the orchestration of immune responses, and are thus key targets in cancer vaccine design. Since the 2010 FDA approval of the first cancer DC-based vaccine (Sipuleucel-T), there has been a surge of interest in exploiting these cells as a therapeutic option for the treatment of tumors of diverse origin. In spite of the encouraging results obtained in the clinic, many elements of DC-based vaccination strategies need to be optimized. In this context, the use of experimental cancer models can help direct efforts toward an effective vaccine design. This paper reviews recent findings in murine models regarding the antitumoral mechanisms of DC-based vaccination, covering issues related to antigen sources, the use of adjuvants and maturing agents, and the role of DC subsets and their interaction in the initiation of antitumoral immune responses. The summary of such diverse aspects will highlight advantages and drawbacks in the use of murine models, and contribute to the design of successful DC-based translational approaches for cancer treatment. © 2015 Mac Keon, Ruiz, Gazzaniga and Wainstok. |
| author |
Gazzaniga, Silvina N. |
| author_facet |
Gazzaniga, Silvina N. |
| author_sort |
Gazzaniga, Silvina N. |
| title |
Dendritic cell-based vaccination in cancer: Therapeutic implications emerging from murine models |
| title_short |
Dendritic cell-based vaccination in cancer: Therapeutic implications emerging from murine models |
| title_full |
Dendritic cell-based vaccination in cancer: Therapeutic implications emerging from murine models |
| title_fullStr |
Dendritic cell-based vaccination in cancer: Therapeutic implications emerging from murine models |
| title_full_unstemmed |
Dendritic cell-based vaccination in cancer: Therapeutic implications emerging from murine models |
| title_sort |
dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models |
| publishDate |
2015 |
| url |
https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_16643224_v6_nMAY_p_MacKeon http://hdl.handle.net/20.500.12110/paper_16643224_v6_nMAY_p_MacKeon |
| work_keys_str_mv |
AT gazzanigasilvinan dendriticcellbasedvaccinationincancertherapeuticimplicationsemergingfrommurinemodels |
| _version_ |
1768543250819317760 |